Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Immunoblastic Lymphadenopathy 1

Interventions

Cyclophosphamide 15fludarabine phosphate 11Bortezomib 8Filgrastim 7fludarabine 6Vorinostat 6Etoposide 6tanespimycin 5Prednisone 5Peripheral Blood Stem Cell Transplantation 5Doxorubicin 5Busulfan 5aldesleukin 4Vincristine 4Tacrolimus 4Paclitaxel 4Lenalidomide 4Gemcitabine 4sargramostim 3nelarabine 3Whole-Body Irradiation 3Topotecan 3Leucovorin 3Irinotecan 3Fluorouracil 3Everolimus 3Dexamethasone 3Dasatinib 3Cytarabine 3Carboplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × Abatacept × Clear all
NCT07388563 2026-05-08

Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Suspended
20 enrolled
LymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡